Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration Matthew Oram History of Psychiatry, 2016, 27, (3), 290-306. Doi : 10.1177/0957154X16648822 Abstract Over the 1950s and early 1960s, the use of the hallucinogenic drug lysergic acid diethylamide (LSD) to facilitate psychotherapy was a promising field of psychiatric research in the USA. However, during the 1960s, research began to decline, before coming to a complete halt in the mid-1970s. This has commonly been explained through the increase in prohibitive federal regulations during the 1960s that aimed to curb the growing recreational use of the drug. However, closely examining the Food and Drug [...]
Lire la suiteMedical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteEfficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962 Matthew ORAM Journal of the History of Medicine and Allied Sciences, 2012, Volume 69, Number 2, 221-250. doi:10.1093/jhmas/jrs050 ABSTRACT. The decline in therapeutic research with lysergic acid diethylamide (LSD) in the United States over the course of the 1960s has commonly been attributed to the growing controversy surrounding its recreational use. However, research difficulties played an equal role in LSD psychotherapy’s demise, as they frustrated researchers’ efforts to clearly establish the efficacy of treatment. Once the Kefauver Harris Drug Amendments of 1962 introduced the requirement that proof of efficacy be established through controlled clinical [...]
Lire la suiteLSD before Leary - Sidney Cohen' s Critique of 1950s Psychedelic Drug Research Steven J. Novak Isis, 1997, Vol. 88, No. 1, pp. 87-110. http://links.jstor.org/sici?sici=0021-1753%28199703%2988%3A1%3C87%3ALBLSCC%3E2.0.CO%3B2-W ABSTRACT In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychoto-mimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were [...]
Lire la suiteIbogaine : A Novel Anti-Addictive Compound. A Comprehensive Literature Review Jonathan Freedlander Journal of Drug Education and Awareness, 2003 https://www.researchgate.net/publication/287670047_Ibogaine_A_novel_anti-addictive_compound Introduction and History Ibogaine is a naturally occurring indole alkaloid, found in a variety of African shrubs of the Tabernathe genus (Obach, Pablo, and Mash, 1998). The root of the Tabernanthe iboga plant (also known as eboga) is the most frequently cited source of ibogaine, and this plant contains 11 other known psychoactive constituents (Popik, and Skolnick, 1999). Chemically, ibogaine is classified as a tryptamine, being a rigid analogue of melatonin, and is structurally similar to harmaline, another natural alkaloid and psychedelic (Xu et al, [...]
Lire la suitePrice elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis Michael Amlung, Derek D. Reed, Vanessa Morris, Elizabeth R. Aston, Jane Metrik & James MacKillop Addiction, 2018, 114, 112–118 doi:10.1111/add.14437 ABSTRACT Background and Aims : The evolving legal status of cannabis world-wide necessitates evidence-based regulatory policies to minimize risks associated with cannabis misuse. A prominent concern is the impact legalization may have on the illegal cannabis market, including whether illegal cannabis will serve as a substitute for legal cannabis. Empirical data on this issue are virtually non-existent. This study used behavioral economics to investigate substitutability of legal and illegal cannabis in legalized catchment areas [...]
Lire la suitehttp://psychedelic-library.org/lsdmenu.htm Alas! the forbidden fruits were eaten, And thereby the warm life of reason congealed. A grain of wheat eclipsed the sun of Adam, Like as the Dragon's tail dulls the brightness of the moon. — Rumi: Masnavi I Ma'navi Introductory Papers The Exploration of Experience by: Humphrey Osmond, an excerpt from his 1957 paper "A Review of the Clinical Effects of Psychotomimetic Agents" Psychedelics, Technology, Psychedelics by: Bernard Aaronson and Humphry Osmond, the introductory chapter to PSYCHEDELICS, the Uses and Implications of Hallucinogenic Drugs Psychedelics and the Future by Humphry Osmond and Bernard S. Aaronson Request for a Public Hearing to: The Hearing Clerk, Department of Health, Education and Welfare Menus Psychotherapy and Psychedelic Drugs Psychedelic Research [...]
Lire la suiteStates Want Pot to Grow Greener as Legal Cannabis Expands Bloomberg Environment, Posted July 19, 2019, 12:01 PM https://news.bloombergenvironment.com/environment-and-energy/states-want-pot-to-grow-greener-as-legal-cannabis-expands Sustainability considered as part of legalization Regulations address pesticides, air quality As more states legalize recreational and medical marijuana, they’re confronting the reality that cannabis production involves using huge amounts of pesticides, energy, and water, while generating tons of plant and packaging waste. The result is a patchwork of air, water, pesticide, and waste regulations for the industry across dozens of states, even as the substance remains illegal at the federal level. States like Michigan, where the Marijuana Regulatory Agency will begin accepting business licenses in [...]
Lire la suiteThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]
Lire la suiteCannabis à usage thérapeutique, la longue marche, Dr Bertrand Lebeau-Leibovici, UFCM, Strasbourg, 28 juin 2019
Lire la suite